AU6468199A - Method to treat haemophilia by (in vivo) gene therapy with retroviral vectors - Google Patents

Method to treat haemophilia by (in vivo) gene therapy with retroviral vectors

Info

Publication number
AU6468199A
AU6468199A AU64681/99A AU6468199A AU6468199A AU 6468199 A AU6468199 A AU 6468199A AU 64681/99 A AU64681/99 A AU 64681/99A AU 6468199 A AU6468199 A AU 6468199A AU 6468199 A AU6468199 A AU 6468199A
Authority
AU
Australia
Prior art keywords
vivo
gene therapy
retroviral vectors
treat haemophilia
haemophilia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64681/99A
Inventor
Marinee K. L. Chuah
Thierry Van Den Driessche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Publication of AU6468199A publication Critical patent/AU6468199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
AU64681/99A 1998-09-23 1999-09-21 Method to treat haemophilia by (in vivo) gene therapy with retroviral vectors Abandoned AU6468199A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98203203 1998-09-23
EP98203203 1998-09-23
PCT/EP1999/007384 WO2000017375A2 (en) 1998-09-23 1999-09-21 Method to treat haemophilia by in vivo gene therapy with retroviral vectors

Publications (1)

Publication Number Publication Date
AU6468199A true AU6468199A (en) 2000-04-10

Family

ID=8234151

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64681/99A Abandoned AU6468199A (en) 1998-09-23 1999-09-21 Method to treat haemophilia by (in vivo) gene therapy with retroviral vectors

Country Status (2)

Country Link
AU (1) AU6468199A (en)
WO (1) WO2000017375A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0400443D0 (en) 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
CN1148228C (en) 2000-08-30 2004-05-05 夏家辉 Gene medicine for treating hemophilia B and its preparing process
GB0325379D0 (en) * 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
US20100256062A1 (en) 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
BR112015013311A2 (en) 2012-12-07 2017-11-14 Haplomics Inc tolerance induction and factor 8 mutation repair
EP3155098A4 (en) * 2014-06-11 2018-01-03 Howard, Tom E. FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION AND RELATED CDNAs, COMPOSITIONS, METHODS AND SYSTEMS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0951544A2 (en) * 1996-07-03 1999-10-27 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of human disease
EP0980264A2 (en) * 1997-05-16 2000-02-23 Leuven Research & Development vzw Mammalian cell transduction for use in gene therapy

Also Published As

Publication number Publication date
WO2000017375A3 (en) 2000-07-27
WO2000017375A2 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
AU2882299A (en) Anti-asthma therapy
AU2543795A (en) Methods of in vivo gene delivery
AU3737297A (en) Bacteriophage-mediated gene therapy
IL181695A0 (en) Methods for cultivating cells and propagating viruses
AU3818300A (en) Treating hair by targeting enzymes
AU7969698A (en) Munitions treatment by acid digestion
IL139936A0 (en) Gene therapy method
HUP0104046A3 (en) Adenovirus-mediated gene therapy
AU6468199A (en) Method to treat haemophilia by (in vivo) gene therapy with retroviral vectors
AU4401297A (en) Improved retroviral vectors for gene therapy
AU2088897A (en) Methods for cell mobilization using in vivo treatment with hyaluronan (ha)
AU1449501A (en) Iontophoretic treatment system
AU3047299A (en) Methods of delivering glp-1
AU6006800A (en) Treating cells
AU2350997A (en) Novel adenoviral vector for transferring human genes in vivo
AU3036197A (en) Adenovirus vectors for gene therapy
EP1084236A4 (en) Novel adenoviral vectors for gene therapy
AU6016499A (en) Medical treatment trolley
AU6853100A (en) Treated leather
AU3866799A (en) Cytoplasmic antiproteinase-3 coding sequence in gene therapy
AU8105798A (en) Mammalian cell transduction for use in gene therapy
AU4552700A (en) Gene therapy
CA2475337A1 (en) Methods for cultivating cells and propagating viruses
GB9923381D0 (en) The uses of cell-specific splicing in gene therapy
AU2003203672A1 (en) Methods for promoting cell transfection in vivo

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase